Europe Life Sciences Weekly Signal #53: MFN Drug Pricing Is Becoming an Enterprise Deal
The nine new MFN agreements are not one pricing deal. Washington is combining Medicaid access, future launch pricing, manufacturing and tariff exposure into company-specific enterprise bargains.









